ABBV closed at $286.74 on October 26, up 0.39% from $285.64, after trading between $285.18 and $289.59 on 4.32 million shares, 0.82x the 20-day average of 5.30 million and 0.89x the 60-day average of 4.86 million. The macro backdrop improved modestly as fell to 18.39 from 19.45, but the 10-year Treasury yield held at 4.986% and still exceeds ABBV's 2.42% dividend yield; the S&P 500 rose 0.70%, the Dow 0.28%, and the Nasdaq 0.82%, so ABBV's low-beta 0.228 profile lagged the rally. The stock remains 1.60% below its $291.40 52-week high and 50.32% above its $190.75 low, with price 4.22% above ($275.12), 7.44% above ($266.89), and 19.82% above ($239.31), while sits 11.53% above . Momentum is constructive but decelerating: histogram eased to 0.644 from 0.846, is 67.09, and rose to a new window high of 95.02 million from 37.98 million on September 30, confirming accumulation even as latest volume ran below average. Fundamentals remain solid, with 72.79% gross margin, 40.04% operating margin, 10.2% revenue growth, $16.87 billion of free cash flow, a 3.33% FCF yield, and a 2.42% dividend yield, but valuation is fair rather than cheap at 17.74x forward on FY27 consensus of $16.202 and 20.55x FY26 of $13.954. The normalized is near 1.10x; the supplied 0.581 is distorted by a 290.4% GAAP growth input. Estimate momentum remains the weakest link: FY26 is down 1.31% over 90 days and 0.39% over 30 days, with 10 downward and zero upward revisions in the last 30 days, while Q3 consensus of $3.775 is down 1.94% over 90 days. The consensus mean target of $284.79 is 0.68% below spot and the median of $289.00 is 0.79% above, while the $200-$328 range implies roughly -30.3% to +14.4%; Goldman Sachs raised its target to $294 from $258 on October 23 and Barclays raised to $325 from $300 on October 21, so sell-side targets are firming even as estimates drift lower. The balance sheet is serviceable but not robust: net debt is $64.32 billion, cash-to-debt is 0.09x, current ratio is 0.81, quick ratio is 0.49, and operating cash flow to debt is 0.28x. The October 30 Q3 2026 report is now three days away, with consensus near $3.775 and bundled coverage citing revenue near $17.36 billion (+10.02% year over year), so the next month is event-driven rather than a clean technical setup. The long-term thesis remains intact on SKYRIZI/RINVOQ growth of 24.4%/24.5% in Q2 against Humira -35.9% and Imbruvica -29.4%, but the stock is priced for a successful transition while estimates are still drifting lower. The stance remains BUY for long-term investors on franchise durability and cash generation, but the one-month and six-month views stay HOLD because earnings risk, negative revisions, and a consensus target below spot cap near-term upside.
Decision
Live price
$286.74
Recommendation score
65%
65%
Confidence
63%
63%
Outlook by horizon
1M
HOLD
Near
6M
HOLD
Mid
1Y
BUY
Long
Primary catalyst
The October 30 Q3 2026 earnings release is the single most market-moving near-term item: consensus is approximately $3.775 and bundled coverage cites revenue near $17.36 billion (+10.02% year over year), while FY26 estimates have drifted lower and the mean target sits below spot. The report's immunology growth and any FY26 guidance adjustment will determine whether the $291.40 breakout attempt resumes; a miss or guidance cut could gap the stock below ordinary stop levels.
Hold a core position but do not chase at $286.74 ahead of earnings: is 18.39, is 67.09, the stock is 1.60% below its 52-week high, the mean target of $284.79 is below spot, and Q3 earnings are three days away. Cap any new pre-earnings addition at half a normal tranche and prefer the $275-$282 pullback zone or post-earnings confirmation.
Thesis Snapshot
Why It Works
ABBV combines resilient pharmaceutical demand with a genuine, if incomplete, franchise transition: SKYRIZI and RINVOQ grew 24.4% and 24.5% in Q2, revenue grew 10.2%, adjusted rose 22.9% year over year, and $16.87 billion of free cash flow supports a 2.42% dividend yield with a 3.33% FCF yield. A normalized near 1.10x is reasonable against roughly 16.1% FY27 growth, and the primary trend remains constructive with price 19.82% above , 11.53% above , and at 95.02 million versus 37.98 million on September 30. Since the prior run, ABBV advanced from $285.64 to $286.74; the prior $274-$282 entry zone worked and price pushed to $289.08 on October 20 before a light-volume pullback, and the $291.40-$300 exit zone remains the relevant scale-out area, though the risk/reward for new money is less attractive than it was a week ago. Goldman Sachs raising its target to $294 from $258 on October 23, alongside Barclays at $325 and Guggenheim at $288, shows sell-side conviction has not broken even as estimates drift. The September 30 zumilokibart Phase 2 data plus the Valkai AI collaboration add longer-dated optionality.
What Breaks It
The strongest argument against owning ABBV here is that the stock sits 1.60% below its 52-week high while FY26 consensus has fallen 1.31% over 90 days with 10 downward and zero upward revisions in the last 30 days, and the mean target of $284.79 is now below spot. Investors appear to be paying in advance for a successful post-Humira transition before estimates confirm it. Humira fell 35.9% and Imbruvica 29.4% in Q2, so any deceleration in SKYRIZI or RINVOQ would expose the forecast growth assumptions long before newer pipeline drugs like zumilokibart contribute revenue. Net debt of $64.32 billion, a 0.49 quick ratio and a 4.986% Treasury yield amplify the consequences of weaker cash-flow expectations or multiple compression, and a 190.4% GAAP payout ratio, even if distorted, keeps the dividend-coverage debate alive. The stock is also technically extended at 19.82% above with at 67.09 and hard resistance at $291.40, and it faces a binary Q3 print in three days amid a at 18.39. The short thesis is that legacy erosion and consensus cuts outrun the replacement franchise, but short interest is only 1.02% of float with a 3.93 short ratio and no historical series is supplied to show whether bearish positioning is building.
A daily close below the rising $275.12 on volume above the 20-day average of roughly 5.30 million shares would invalidate the current intermediate bullish structure and require a full fundamental and technical reassessment; a break of the $266.89 would confirm it.
Q3 earnings on October 30 are three days away, with consensus near $3.775 and revenue estimates near $17.36 billion; near-record pricing plus a $284.79 mean target below spot raises the probability of a gap lower on a miss or cautious guidance.
FY26 consensus of $13.95384 is down 1.31% over 90 days and 0.39% over 30 days, with 10 downward and zero upward revisions; a continuation of that drift would erode the roughly 16.1% FY27 growth embedded in the 17.74x forward multiple.
Replacement-cycle concentration is high: Q2 SKYRIZI and RINVOQ grew 24.4% and 24.5% while Humira fell 35.9% and Imbruvica fell 29.4%; even a modest deceleration in the two growth assets would undermine the earnings bridge.
Net debt of $64.32 billion, cash-to-debt of 0.09x, a current ratio of 0.81 and a quick ratio of 0.49 leave limited slack, and a 4.986% 10-year yield still exceeds the 2.42% dividend yield.
The stock is 19.82% above with at 67.09 and hard resistance at $291.40; a failed breakout plus a at 18.39 and binary earnings could trigger fast mean reversion, while short interest of 1.02% of float offers no squeeze cushion.
Watch Next
Next earnings: Oct 30, 2026
The October 30 Q3 2026 earnings release is the single most market-moving near-term item: consensus is approximately $3.775 and bundled coverage cites revenue near $17.36 billion (+10.02% year over year), while FY26 estimates have drifted lower and the mean target sits below spot. The report's immunology growth and any FY26 guidance adjustment will determine whether the $291.40 breakout attempt resumes; a miss or guidance cut could gap the stock below ordinary stop levels.
Signal Dashboard
Decision inputs
6 signals
Fundamental
-0.7%
Upside to analyst mean target
At $286.74, ABBV trades at 17.74x forward , which capitalizes FY27 consensus of $16.20158; against FY26 consensus of $13.95384 that implies roughly 16.1% growth and a normalized of about 1.10x, which is reasonable for a large-cap immunology franchise. The supplied 0.581 relies on a 290.4% GAAP earnings-growth input and should not be used. FY26 is 20.55x, while the 81.0x trailing is distorted by a depressed GAAP earnings base and the -85.36x is uninformative because GAAP book equity is negative. is 18.5x and is 7.87x against 10.2% revenue growth, leaving the stock fairly valued with a modest quality premium rather than deeply undervalued. A September 29 Zacks item at a $263.29 share price cited 18.95x forward versus a 16.57x large-cap pharmaceutical industry average and a 1.2x versus 2.17x for the industry, so ABBV screens at a premium multiple but a discount . The consensus mean target of $284.79 is now 0.68% below the $286.74 share price and the $289.00 median is only 0.79% above spot, while the $200-$328 range implies roughly -30.3% to +14.4% and reflects genuine disagreement about the durability of the post-Humira replacement cycle.
Technical
Bullish
Trend quality
At $286.74, ABBV sits 4.22% above its rising of $275.12, 7.44% above its of $266.89 and 19.82% above its of $239.31, with 11.53% above and above . That is a fully established bullish alignment rather than a fresh cross within the supplied window, and the long-term trend is unambiguously up. The October 26 session opened at $287.05, dipped to $285.18, made a $289.59 high and closed at $286.74 near the high, holding above the October 23 low of $282.30 and the October 22 low of $278.01. Immediate support is the $285.18 October 26 low, with the rising at $275.12 as the structural line and the at $266.89 as the intermediate trend backstop.
Earnings
3d
Improving
Q2 2026 adjusted of $3.65 beat the $3.608 estimate by 1.15% and rose 22.9% year over year, the strongest sequential step in the supplied six-quarter history; the bundle contains no post-report share reaction, and the Improving label refers to realized progression even though forward FY26 consensus has fallen 1.31% over 90 days and Q3 consensus of $3.7748 is down 1.94% over 90 days, with the Q3 report due October 30, three days away.
News
Mixed-Bullish
Headline tone
The October 30 Q3 2026 earnings release is the single most market-moving near-term item: consensus is approximately $3.775 and bundled coverage cites revenue near $17.36 billion (+10.02% year over year), while FY26 estimates have drifted lower and the mean target sits below spot. The report's immunology growth and any FY26 guidance adjustment will determine whether the $291.40 breakout attempt resumes; a miss or guidance cut could gap the stock below ordinary stop levels.
Macro
Neutral
4.99% 10Y / 18.4 VIX
at 18.39 and the 10-year yield at 4.986% keep the tape cautious; ABBV's low beta of 0.228 and 2.42% dividend yield support defensive demand, but the elevated 10-year yield still limits multiple expansion into the October 30 print.
Stability
Stable Compounder
Core Anchor
ABBV remains a Stable Compounder because its pharmaceutical cash flows are recurring and high-margin: gross margin is 72.79%, operating margin is 40.04%, margin is 47.78%, and free cash flow is $16.87 billion against operating cash flow of $19.51 billion. It can serve as a Core Anchor for healthcare exposure and dividend income, but it is not a cash substitute: net debt is $64.32 billion, cash-to-debt is 0.09x, the current ratio is 0.81, and the quick ratio is 0.49. Drawdown risk is Medium given 20-day realized volatility of 21.21%, a beta of only 0.228, a 4.986% 10-year Treasury yield, a share price 1.60% below its 52-week high, and Q3 earnings three days away. Thesis durability is Medium until replacement growth from SKYRIZI and RINVOQ is confirmed by stabilizing forward estimates and the pipeline demonstrates commercial value beyond zumilokibart's Phase 2 signal.
Analyst Spread
Mean Target
$284.79
High / Low
$200 / $328
Median Target
$289.00
Consensus range
$200 - $328
— analysts
Mean
$200$285$328
Consensus
The $284.79 mean target is 0.68% below the $286.74 share price and the $289.00 median is 0.79% above spot, so consensus offers almost no valuation cushion after the run to within 1.60% of the 52-week high. The $200 low and $328 high represent roughly 30.3% downside and 14.4% upside, reflecting real disagreement about the durability of the post-Humira replacement cycle and pipeline contribution. The rating mix of 30 marks (8 Strong Buy, 16 Buy, 5 Hold, 1 Strong Sell) is stable, but the separate analyst-count field is null, so the total should not be treated as a confirmed unique-analyst count. The current_price_target field equals the last price and is not an independent consensus signal. Recent target increases, led by Goldman Sachs at $294 and Barclays at $325, show sell-side posture remains constructive even as estimates drift lower.
Positioning Pulse
Insider Signal
Neutral
Net Bias
No recent activity
Insider Own.
0.1%
Institutional Own.
77.4%
Interpretation
The available insider record is not interpretable as a confirmed discretionary trade, so it provides no reliable signal about management's near-term confidence and should be treated as an absence of information rather than a negative.
Notable activity
The only supplied record lists CEO Richard A. Gonzalez with 6,000 shares, but the date field reads '70', the transaction type is blank and the dollar value is unavailable, so it cannot be classified as a discretionary open-market purchase or sale.
Market Context
Industry
Drug Manufacturers - General
Mixed-Bullish
Sentiment
24
Tracked names
5
Grouping
industry
Drug Manufacturers - General industry is currently Mixed-Bullish with an average recommendation score near 60. capital and conviction are improving across the group, and leadership is concentrated in LLY, JNJ, AMGN.
Rotation Drivers
Average recommendation deltas are trending higher across Drug Manufacturers - General industry, which suggests improving risk appetite inside the group.
2 names are rated bullish versus 0 bearish names, keeping the group tone mixed-bullish.
Leadership is concentrated in LLY, JNJ, AMGN, so those names are the cleanest read on group-level capital rotation.
The relevant rotation narrative is selective interest in biopharma franchises with credible growth after legacy blockbusters rather than broad sector beta. Q2 SKYRIZI and RINVOQ sales grew 24.4% and 24.5% respectively against Humira -35.9% and Imbruvica -29.4%, while the September 30 zumilokibart Phase 2 update adds pipeline evidence and Goldman Sachs/Barclays target increases reinforce the narrative. ABBV's 9.14% one-month return and 95.37% 52-week range position show capital favoring this story, but the 1.31% decline in FY26 consensus over 90 days shows earnings estimates have not yet confirmed the full transition.
The October 30 Q3 report will test whether immunology growth can support FY26 consensus near $13.95 after the recent zumilokibart Phase 2 update and the latest target increases.
Q2 SKYRIZI revenue reached $5.505 billion, up 24.4%, and RINVOQ reached $2.525 billion, up 24.5%, while Humira fell 35.9% and Imbruvica fell 29.4%.
Goldman Sachs raised its target to $294 from $258 on October 23 and Barclays raised to $325 from $300 on October 21; ABBV returned 9.14% over one month versus 9.68% year to date, signs of selective interest rather than broad fund-flow evidence.
Defensive Dividend Rotation
Score: 54
Mixed-Bullish
ABBV's 0.228 beta, 2.42% dividend yield and Dividend King status fit a defensive-income role, and recent coverage grouped it with JNJ and KO as reliable payers that had outperformed the S&P 500 in 2026. The October 26 tape was risk-on, with down to 18.39 and major indices higher, so ABBV's +0.39% gain lagged the S&P 500's +0.70% and the Nasdaq's +0.82%; even with the 10-year Treasury yield at 4.986%, the spread versus ABBV's 2.42% yield remains negative, so flows into this theme are likely to be selective and valuation-sensitive rather than a broad rotation.
at 18.39 and the 10-year yield near 4.99% sharpen the defensive-income trade-off just before ABBV's October 30 earnings.
ABBV's 0.228 beta and 2.42% dividend yield support defensive-income demand, while the 4.986% Treasury yield keeps relative income appeal muted.
Recent Zacks coverage named ABBV alongside JNJ and KO as Dividend Kings that had outperformed the S&P 500 in 2026, reinforcing the defensive-income narrative with a 5.7% five-year annualized dividend growth rate.
Key Stats
23 metrics total
Market Cap
$506.70B
P/E (TTM)
81.0
Forward P/E
17.7
Revenue Growth
10.2%
ROE
0.0%
Beta
0.23
Full Metric Set
17 additional stats
Valuation Stack
Multiples and cash-flow framing.
Price / Sales
7.9
Price / Book
-85.4
EV / EBITDA
18.5
Quality & Balance Sheet
Margins, leverage, and liquidity.
Gross Margin
72.8%
Operating Margin
40.0%
Debt / Equity
0.0
Current Ratio
0.81x
Quick Ratio
0.49x
Positioning & Range
Short interest and 52-week location.
Short % Float
1.0%
Short Ratio
3.93x
52W High
$291.40
52W Low
$190.75
From 52W High
-1.6%
From 52W Low
50.3%
Company Classification
Sector and industry context.
Sector
Healthcare
Industry
Drug Manufacturers - General
Additional Signals
Free Cash Flow
$16870250496.00
Detailed Analysis
Valuation
At $286.74, ABBV trades at 17.74x forward , which capitalizes FY27 consensus of $16.20158; against FY26 consensus of $13.95384 that implies roughly 16.1% growth and a normalized of about 1.10x, which is reasonable for a large-cap immunology franchise. The supplied 0.581 relies on a 290.4% GAAP earnings-growth input and should not be used. FY26 is 20.55x, while the 81.0x trailing is distorted by a depressed GAAP earnings base and the -85.36x is uninformative because GAAP book equity is negative. is 18.5x and is 7.87x against 10.2% revenue growth, leaving the stock fairly valued with a modest quality premium rather than deeply undervalued. A September 29 Zacks item at a $263.29 share price cited 18.95x forward versus a 16.57x large-cap pharmaceutical industry average and a 1.2x versus 2.17x for the industry, so ABBV screens at a premium multiple but a discount . The consensus mean target of $284.79 is now 0.68% below the $286.74 share price and the $289.00 median is only 0.79% above spot, while the $200-$328 range implies roughly -30.3% to +14.4% and reflects genuine disagreement about the durability of the post-Humira replacement cycle.
Balance Sheet
Cash of $6.57 billion against total debt of $70.88 billion leaves $64.32 billion of net debt, equal to -12.69% of the $506.70 billion market cap, with cash-to-debt of 0.09x and operating-cash-flow-to-debt of 0.28x. Free cash flow of $16.87 billion is 86.5% of $19.51 billion of operating cash flow and equals a 3.33% FCF yield, enough to service debt and fund the dividend. The current ratio of 0.81 and quick ratio of 0.49 indicate limited working-capital flexibility, and and are unavailable because GAAP equity is negative. The balance sheet is serviceable on current cash generation but not exceptionally liquid, and it leaves little slack for a major debt-funded acquisition or a sharp cash-flow disappointment.
Growth
Revenue grew 10.2% year over year, and Q2 2026 adjusted of $3.65 rose 22.9% from $2.97 a year earlier while beating the $3.608 estimate by 1.15%. Q2 SKYRIZI sales were $5.505 billion, up 24.4%, and RINVOQ sales were $2.525 billion, up 24.5%, while Humira fell 35.9% to $756 million and Imbruvica declined 29.4%. The reported 290.4% earnings-growth figure is a GAAP rebound off a depressed base and not an organic growth rate. FY26 to FY27 consensus implies roughly 16.1% growth, but both series have been revised lower, with FY26 down 1.31% and FY27 down 0.79% over 90 days. The bundle does not provide a margin time series, so recent gross or operating margin expansion cannot be independently established.
Business Quality
ABBV has a high-margin profile with 72.79% gross margin, 40.04% operating margin, 47.78% margin, 9.8% profit margin and 10.51% ; is unavailable because book equity is negative. Current and quick ratios of 0.81 and 0.49 are weaker quality markers, while institutional ownership of 77.36% and insider ownership of 0.11% show broad institutional ownership with minimal insider alignment. is 0.228, 20-day realized volatility is 21.21%, and 20-day average dollar volume is approximately $1.46 billion, providing low market sensitivity and deep liquidity but not eliminating single-name, pipeline or earnings-event risk. Business quality supports a premium valuation, but the dependence on two immunology assets for replacement growth prevents treating the franchise as fully defensive.
Capital Allocation
Free cash flow of $16.87 billion and a 3.33% FCF yield comfortably fund the 2.42% dividend yield, even though the reported 190.4% GAAP payout ratio should not be read as a cash-coverage measure. Net debt of $64.32 billion means deleveraging depends on sustained product cash generation, making disciplined pipeline investment and bolt-on deal pricing critical. The zumilokibart Phase 2 program moved into Phase 3 with a selected mid dose, and the Valkai AI R&D collaboration plus the Antibody Developability Consortium membership are strategic investments whose financial returns remain unproven. Shares outstanding stand at 1.767 billion, but no share-count history is supplied to assess net buybacks or dilution.
Estimate Revisions
Estimate momentum is still negative overall. Current-quarter consensus of $3.7748 is down 1.94% over 90 days, 1.81% over 30 days and 0.32% over seven days, with eight downward and zero upward revisions in the last 30 days. Next-quarter consensus of $3.88632 is up 0.48% from 30 days ago ($3.86785) but remains 2.88% below its 90-day level of $4.0016. FY26 consensus of $13.95384 is down 1.31% over 90 days and 0.39% over 30 days, with 10 downward and zero upward revisions in the last 30 days and eight downward in the last seven. FY27 consensus of $16.20158 is down 0.79% over 90 days, with six downward and three upward revisions over 30 days. The recommendation distribution is 8 Strong Buy, 16 Buy, 5 Hold and 1 Strong Sell, essentially unchanged over three months, with no reported upgrades, downgrades or initiations in the last 90 days. Price-target actions remain constructive, however: Goldman Sachs raised to $294 from $258 on October 23, Barclays to $325 from $300 on October 21, UBS to $275 from $260, while RBC maintained $280 and Guggenheim maintained $288.